Vertex Research Group — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2024	Research	$56,292	4
2023	Research	$3,078	22
2022	Research	$3,046	2

Breakdown

Who paid Research payments · program years 2022–2024

E.R. Squibb & Sons, L.L.C. $49,520 2 payments
Sumitomo Pharma America, Inc. $7,504 21 payments
Boehringer Ingelheim RCV GmbH & Co KG $4,904 3 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $487 2 payments

Studies the money was for Research payments · program years 2022–2024

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia $33,520 1 payment
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia $16,000 1 payment
A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression) $6,675 1 payment
Connex 1 $5,391 5 payments
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. $829 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.